Navigation Links
Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007
Date:10/20/2010

FREMONT, Calif., Oct. 20 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, today announced it has dosed the first patient with recent onset of non-arteritic anterior ischemic optic neuropathy (NAION) in its ongoing Phase I study of QPI-1007, the Company's proprietary synthetic siRNA drug candidate for ocular neuroprotection.

The Phase I open-label, dose-escalation study was initiated during the first quarter of 2010 to evaluate the safety, tolerability and pharmacokinetic profile of QPI-1007 in patients with chronic nerve atrophy (Stratum I) and recent onset NAION (Stratum II). Enrollment has been completed, with no dose-limiting toxicities observed, in five of the six cohorts of Stratum I.  Dosing at the highest planned dose level has been initiated in this patient population. Up to 30 NAION patients will be enrolled in Stratum II. In addition to safety and pharmacokinetic assessments, changes in visual acuity and visual field following the administration of QPI-1007 will be measured.

Dr. Daniel Zurr, Quark's Chief Executive Officer, stated, "After escalating to the highest planned dose of QPI-1007 in patients with chronic nerve atrophy, we are excited to dose the first NAION patient in our ongoing clinical study of QPI-1007, which has demonstrated significant neuroprotective activity in preclinical studies."

About the Phase I Study

The Phase I, open-label, dose-escalation study will assess the safety, tolerability, and pharmacokinetic profile of QPI-1007 in patients with chronic nerve atrophy (Stratum I) and recent onset NAION (Stratum II).  The study is expected to enroll up to 66 patients to receive a single intravitreal injection of QPI-1007 at varying doses with assessments of safety and tolerability for 12 months post-injection.  Secondary outcome measures include describing any anatomical changes in the optic nerve h
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , August 29, 2014 ... Seed Oil Market by Extraction type (SFE, Cold ... & Personal Care, Pharmaceutical, Food Supplements, Fragrance, & Others) ... by MarketsandMarkets, defines and segments the Amaranth Seed ... the market size in terms of value. The ...
(Date:8/29/2014)... Corporation , a neurodiagnostics medical device company based in ... Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, FRCSEd  was ... " Teo Forcht Dagi is an experienced leader with ... said Remis Bistras , President and CEO of Vittamed. ... entrepreneurial expertise to our Board." Dr. Dagi is ...
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will ... the Australian and New Zealand Forensic Science Society,s ... Sciences in Adelaide, Australia . ... concerning the advancements that hyperspectral imaging can bring ... Jeffrey Beckstead , Director of Product Development at ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
(Date:8/30/2014)... August 30, 2014 RB SEO Services, ... SEO service for small businesses. , RBSEO Services knows ... afford costly search engine optimization service. So, the company ... businesses into account. , On being asked about ... introduced this low cost SEO service because many small ...
(Date:8/30/2014)... The establishment and creation of ... one of the main strategies of the Church ... impact around the world. , Architecturally stellar buildings ... executives and trainers deliver L. Ron Hubbard's spiritual ... statistics demonstrate that significant reduction in crime, major ...
(Date:8/30/2014)... 30, 2014 Acne is a common problem millions ... is nothing more than a daily nuisance, for some, it can ... of acne can even lead to dramatic mood swings and depression. ... anything to clear up their skin. In some cases, that can ... through trial and error, those on a quest for clearer skin ...
(Date:8/30/2014)... Seniors Guide, the comprehensive guide to all things senior, ... Disease, Dementia, and Memory Loss . , Country singer Glen ... with the Alzheimer’s, inspired Seniors Guide writers to review the ... movie, out on October 14, 2014, shows a glimpse of ... disease – which inspires a final tour from the musician ...
(Date:8/30/2014)... Manhattan Beach, Calif. (PRWEB) August 30, 2014 ... Carol Francis helps listeners understand how they unknowingly developed insomnia ... and have restful nights during. Tune in to the ... . The show airs live on August 30, and ... For more information on programming, go to DrCarolFrancisTalkRadio.com. ...
Breaking Medicine News(10 mins):Health News:RBSEO Services Introduces Low Cost SEO Service for Small Businesses 2Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Acne Treatment Reviews Added to Popular Treatment Website 2Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis 2
... Rigorous Review of Pertinent Performance Indicators, ... Services, a,leading provider of revenue cycle management ... Emdeon Assistant patient access,solution has earned the ... Association (HFMA)., HFMA,s intensive Peer Review ...
... heart checkup, SAN DIEGO, June 23 ... Health, men are sluggish at reporting health,problems and ... National Men,s Health Month, RealAge.com, the leading,healthy-lifestyle Web ... men,s fingertips., With a few strokes of ...
... for, immunization against diphtheria, tetanus, pertussis, polio and Haemophilus ... ... LYON, France, June 23 Sanofi,Pasteur, the vaccines division of ... Administration (FDA) has licensed Pentacel(R),Diphtheria and Tetanus Toxoids and Acellular ...
... in health care and compensation benefits, CHICAGO, ... employers are managing to maintain a balance in ... released today by,the Society for Human Resource Management ... care costs, combined with the state of the ...
... June 21 Many professionals,world-wide are calling on Louisiana ... on almost the whole state. SB 312 was quietly,pushed ... knowing,it was happening. The professionals are asking Jindal to ... have been part of this discussion,but they were not., ...
... NEW DELHI, India, June 20 The United ... non-governmental,organization Save the Children to assist people affected ... India., Shortages have emerged in recent months ... resulted in rapidly growing rat infestations in,crop-growing areas. ...
Cached Medicine News:Health News:Emdeon Assistant Earns HFMA's Peer Review Designation 2Health News:Men Won't Ask for Directions - Even About Their Health! 2Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 2Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 3Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 4Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 5Health News:Despite Economic Downturn, Employee Benefits Remain Stable in 2008 2Health News:Professionals Ask Governor Jindal to Veto Unfair Fluoridation Bill 2
... The ABI Prism 7000 Sequence ... PCR system that detects and quantitates ... cycle-by-cycle detection of accumulated PCR product ... cycling, fluorescence detection, and application-specific software ...
RIA kit for the determination of autoantibodies to the TSH receptor (TSHR) in serum [with calibrators]....
ELISA kit for the determination of autoantibodies to the TSH receptor (TSHR) in serum....
Coated-Tube (CT) RIA kit for the determination of autoantibodies to the TSH receptor (TSHR) in serum...
Medicine Products: